Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Modalis Therapeutics Corporation ( (JP:4883) ) has provided an announcement.
Modalis Therapeutics Corporation reported its consolidated financial results for the nine months ending September 30, 2025, showing a significant increase in losses compared to the previous year. The company’s financial position weakened, with a decline in total assets and net assets, while the capital adequacy ratio also decreased. Despite these challenges, the company did not revise its dividend forecast, indicating a cautious approach amidst financial uncertainties.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, operating in the biotechnology industry. The company focuses on developing innovative therapies and treatments, leveraging its expertise in genetic modulation technologies.
Average Trading Volume: 1,373,390
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.89B
Learn more about 4883 stock on TipRanks’ Stock Analysis page.